Rationale for Correct Answer
The correct answer is: KRAS G12C only
The FDA-approved agents adagrasib and sotorasib are approved for treating advanced and metastatic NSCLC in patients whose tumors carry KRAS G12C mutations only.1 These agents can only react with cysteine residues, so they have no activity against NSCLC tumors carrying KRAS G12V, G12A, or G12D mutations.2
References:
1. U.S. Food & Drug Administration (FDA). Oncology (Cancer) / Hematologic Malignancies Approval Notifications. Reviewed June 20, 2023. Accessed June 20, 2023. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
2. Liu J et al. Cancer Gene Ther. 2022;29:875-878.